PHARMING GROUP NV (PHARM.AS) Stock Fundamental Analysis

AMS:PHARM • NL0010391025

1.393 EUR
+0.01 (+0.72%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to PHARM. PHARM was compared to 75 industry peers in the Biotechnology industry. PHARM has an average financial health and profitability rating. PHARM has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

  • In the past year PHARM has reported negative net income.
  • In the past year PHARM had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: PHARM reported negative net income in multiple years.
  • In multiple years PHARM reported negative operating cash flow during the last 5 years.
PHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFPHARM.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • The Return On Assets of PHARM (0.08%) is better than 70.13% of its industry peers.
  • PHARM's Return On Equity of 0.14% is fine compared to the rest of the industry. PHARM outperforms 74.03% of its industry peers.
  • PHARM's Return On Invested Capital of 7.08% is amongst the best of the industry. PHARM outperforms 81.82% of its industry peers.
Industry RankSector Rank
ROA 0.08%
ROE 0.14%
ROIC 7.08%
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
PHARM.AS Yearly ROA, ROE, ROICPHARM.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.11%, PHARM is in the better half of the industry, outperforming 71.43% of the companies in the same industry.
  • PHARM's Operating Margin of 10.06% is fine compared to the rest of the industry. PHARM outperforms 79.22% of its industry peers.
  • With an excellent Gross Margin value of 89.90%, PHARM belongs to the best of the industry, outperforming 83.12% of the companies in the same industry.
  • PHARM's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.06%
PM (TTM) 0.11%
GM 89.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
PHARM.AS Yearly Profit, Operating, Gross MarginsPHARM.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • PHARM has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for PHARM has been increased compared to 1 year ago.
  • The number of shares outstanding for PHARM has been increased compared to 5 years ago.
  • Compared to 1 year ago, PHARM has an improved debt to assets ratio.
PHARM.AS Yearly Shares OutstandingPHARM.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
PHARM.AS Yearly Total Debt VS Total AssetsPHARM.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • PHARM has an Altman-Z score of 1.09. This is a bad value and indicates that PHARM is not financially healthy and even has some risk of bankruptcy.
  • PHARM has a Altman-Z score (1.09) which is in line with its industry peers.
  • PHARM has a debt to FCF ratio of 2.49. This is a good value and a sign of high solvency as PHARM would need 2.49 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 2.49, PHARM belongs to the best of the industry, outperforming 88.31% of the companies in the same industry.
  • PHARM has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • PHARM's Debt to Equity ratio of 0.46 is in line compared to the rest of the industry. PHARM outperforms 57.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 2.49
Altman-Z 1.09
ROIC/WACC1.22
WACC5.82%
PHARM.AS Yearly LT Debt VS Equity VS FCFPHARM.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

2.3 Liquidity

  • A Current Ratio of 3.16 indicates that PHARM has no problem at all paying its short term obligations.
  • PHARM has a Current ratio of 3.16. This is in the better half of the industry: PHARM outperforms 64.94% of its industry peers.
  • A Quick Ratio of 2.39 indicates that PHARM has no problem at all paying its short term obligations.
  • The Quick ratio of PHARM (2.39) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.16
Quick Ratio 2.39
PHARM.AS Yearly Current Assets VS Current LiabilitesPHARM.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • PHARM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.30%, which is quite impressive.
  • The Revenue has grown by 26.78% in the past year. This is a very strong growth!
  • PHARM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.64% yearly.
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%

3.2 Future

  • Based on estimates for the next years, PHARM will show a very strong growth in Earnings Per Share. The EPS will grow by 53.15% on average per year.
  • Based on estimates for the next years, PHARM will show a quite strong growth in Revenue. The Revenue will grow by 10.63% on average per year.
EPS Next Y111.44%
EPS Next 2Y85.83%
EPS Next 3Y65.17%
EPS Next 5Y53.15%
Revenue Next Year28.88%
Revenue Next 2Y18.74%
Revenue Next 3Y13.37%
Revenue Next 5Y10.63%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
PHARM.AS Yearly Revenue VS EstimatesPHARM.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
PHARM.AS Yearly EPS VS EstimatesPHARM.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.1 -0.1 0.2

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • PHARM is valuated quite expensively with a Price/Forward Earnings ratio of 62.86.
  • Based on the Price/Forward Earnings ratio, PHARM is valued a bit cheaper than the industry average as 75.32% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 28.05. PHARM is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 62.86
PHARM.AS Price Earnings VS Forward Price EarningsPHARM.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PHARM is valued cheaply inside the industry as 98.70% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, PHARM is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 2.18
EV/EBITDA 0.87
PHARM.AS Per share dataPHARM.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • PHARM's earnings are expected to grow with 65.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y85.83%
EPS Next 3Y65.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PHARM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARMING GROUP NV

AMS:PHARM (2/27/2026, 7:00:00 PM)

1.393

+0.01 (+0.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-12
Inst Owners21.51%
Inst Owner ChangeN/A
Ins Owners1.39%
Ins Owner ChangeN/A
Market Cap97.05M
Revenue(TTM)362.27M
Net Income(TTM)383.00K
Analysts88.57
Price Target2.19 (57.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)597.09%
Min EPS beat(2)123.3%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)281.14%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)65.03%
EPS beat(12)5
Avg EPS beat(12)12.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.89%
Min Revenue beat(2)1.11%
Max Revenue beat(2)8.68%
Revenue beat(4)4
Avg Revenue beat(4)8.65%
Min Revenue beat(4)1.11%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)1.62%
Revenue beat(12)7
Avg Revenue beat(12)-0.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.9%
PT rev (3m)9.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)377.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-91.06%
Revenue NQ rev (1m)3.45%
Revenue NQ rev (3m)3.45%
Revenue NY rev (1m)2.04%
Revenue NY rev (3m)8.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 62.86
P/S 0.32
P/FCF 2.18
P/OCF 2.15
P/B 0.43
P/tB 0.88
EV/EBITDA 0.87
EPS(TTM)0
EYN/A
EPS(NY)0.02
Fwd EY1.59%
FCF(TTM)0.64
FCFY45.89%
OCF(TTM)0.65
OCFY46.44%
SpS4.4
BVpS3.22
TBVpS1.58
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 0.08%
ROE 0.14%
ROCE 9.44%
ROIC 7.08%
ROICexc 12.44%
ROICexgc 32.23%
OM 10.06%
PM (TTM) 0.11%
GM 89.9%
FCFM 14.51%
ROA(3y)-0.68%
ROA(5y)2.2%
ROE(3y)-1.17%
ROE(5y)5.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score7
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 2.49
Debt/EBITDA 2.33
Cap/Depr 4%
Cap/Sales 0.17%
Interest Coverage 5.94
Cash Conversion 102.18%
Profit Quality 13727.2%
Current Ratio 3.16
Quick Ratio 2.39
Altman-Z 1.09
F-Score7
WACC5.82%
ROIC/WACC1.22
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
EPS Next Y111.44%
EPS Next 2Y85.83%
EPS Next 3Y65.17%
EPS Next 5Y53.15%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
Revenue Next Year28.88%
Revenue Next 2Y18.74%
Revenue Next 3Y13.37%
Revenue Next 5Y10.63%
EBIT growth 1Y355.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year401.72%
EBIT Next 3Y93.29%
EBIT Next 5Y78.86%
FCF growth 1Y309.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y325.01%
OCF growth 3YN/A
OCF growth 5YN/A

PHARMING GROUP NV / PHARM.AS FAQ

What is the ChartMill fundamental rating of PHARMING GROUP NV (PHARM.AS) stock?

ChartMill assigns a fundamental rating of 5 / 10 to PHARM.AS.


What is the valuation status for PHARM stock?

ChartMill assigns a valuation rating of 5 / 10 to PHARMING GROUP NV (PHARM.AS). This can be considered as Fairly Valued.


Can you provide the profitability details for PHARMING GROUP NV?

PHARMING GROUP NV (PHARM.AS) has a profitability rating of 5 / 10.